Medical Economics February 24, 2025
Austin Littrell

Key Takeaways

  • Medtronic’s BrainSense aDBS system dynamically adjusts therapy based on individual brain activity, enhancing Parkinson’s disease treatment.
  • The BrainSense Electrode Identifier reduces initial programming time by 85%, offering precise real-time data for tailored therapy.
  • The ADAPT-PD trial evaluated the safety and effectiveness of aDBS, highlighting its potential to revolutionize Parkinson’s treatment.
  • aDBS technology aims to improve symptom control for patients experiencing motor fluctuations and dyskinesias with conventional DBS.

Real-time neuromodulation offers more precise treatment for Parkinson’s patients.

Medtronic plc, a leading global health care technology company based in Galway, Ireland, has received U.S. Food and Drug Administration (FDA) approval for BrainSense Adaptive deep brain stimulation (aDBS) — the first system of its kind to dynamically adjust therapy...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: FDA, Govt Agencies, Medical Devices, Patient / Consumer, Provider
Related Articles:
Medtronic gains FDA OK for self-adjusting DBS system for Parkinson’s
Chinese medical devices are in health systems across U.S., and the government and hospitals are worried
Siemens raises $1.5B by selling stake in Healthineers imaging division
Valencia Technologies Secures Strategic Investment of $35 Million from Brooks Advisory Group, Appoints James D. Surek as CEO
Device industry scrambles as FDA job cuts cause delays

Share This Article